MetaVia Raises $9.3 Million in Public Offering to Fund Obesity & Metabolic Drug Pipeline
MetaVia Inc. raises $9.3 M in a public offering to speed its obesity drug vanoglipel and dyslipidemia program, despite a 26 % stock dip.
2 minutes to read
MetaVia Inc
MetaVia Inc. Aims to Revolutionize Dyslipidemia Treatment Amid Volatile Stock
MetaVia Inc. develops innovative dyslipidemia therapies amid financial volatility, targeting cardiovascular disease solutions with potential growth once clinical trials succeed.
2 minutes to read
MetaVia Inc Faces Market Volatility Amid Biotech Innovation Efforts
MetaVia Inc, a biopharmaceutical company, faces challenges in a volatile market, but remains committed to developing therapies for dyslipidemia and potentially offers opportunities for future growth.
2 minutes to read